Poggesi I - Search Results

1

General clinical and methodological considerations on the extrapolation of pharmacokinetics and optimization of study protocols for small molecules and monoclonal antibodies in children.

Bouazza N, Dokoumetzidis A, Knibbe CAJ, de Wildt SN, Ambery C, De Cock PA, Gasthuys E, Foissac F, Urien S, Hamberg AK, Poggesi I, Zhao W, Vermeulen A, Standing JF, Tréluyer JM; c4c Expert group on Pharmacometrics. Bouazza N, et al. Among authors: poggesi i. Br J Clin Pharmacol. 2022 Dec;88(12):4985-4996. doi: 10.1111/bcp.15571. Epub 2022 Nov 8. Br J Clin Pharmacol. 2022. PMID: 36256514 Free article. Review.

2

Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.

Stuyckens K, Saad F, Xu XS, Ryan CJ, Smith MR, Griffin TW, Yu MK, Vermeulen A, Nandy P, Poggesi I. Stuyckens K, et al. Among authors: poggesi i. Clin Pharmacokinet. 2014 Dec;53(12):1149-60. doi: 10.1007/s40262-014-0178-6. Clin Pharmacokinet. 2014. PMID: 25204404 Clinical Trial.

3

Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients.

Xu XS, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, Vermeulen A, Poggesi I, Nandy P. Xu XS, et al. Among authors: poggesi i. Clin Cancer Res. 2015 Jul 15;21(14):3170-7. doi: 10.1158/1078-0432.CCR-14-1549. Epub 2015 Mar 31. Clin Cancer Res. 2015. PMID: 25829400 Clinical Trial.

4

Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer.

Xu XS, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, De Porre P, Vermeulen A, Poggesi I, Nandy P. Xu XS, et al. Among authors: poggesi i. Clin Pharmacokinet. 2017 Jan;56(1):55-63. doi: 10.1007/s40262-016-0425-0. Clin Pharmacokinet. 2017. PMID: 27324190 Clinical Trial.

5

Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia.

Zhou W, Parasrampuria DA, Nemat S, Nakahara S, Poggesi I, Massarella J, Zhang L, Appiani C. Zhou W, et al. Among authors: poggesi i. J Clin Pharmacol. 2019 May;59(5):668-676. doi: 10.1002/jcph.1357. Epub 2018 Dec 11. J Clin Pharmacol. 2019. PMID: 30536675

6

Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects.

Axelsen LN, Poggesi I, Rasschaert F, Perez Ruixo JJ, Bruderer S. Axelsen LN, et al. Among authors: poggesi i. Br J Clin Pharmacol. 2021 Jan;87(1):119-128. doi: 10.1111/bcp.14365. Epub 2020 Jun 5. Br J Clin Pharmacol. 2021. PMID: 32415684 Free PMC article.

7

Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective.

Heimbach T, Chen Y, Chen J, Dixit V, Parrott N, Peters SA, Poggesi I, Sharma P, Snoeys J, Shebley M, Tai G, Tse S, Upreti VV, Wang YH, Tsai A, Xia B, Zheng M, Zhu AZX, Hall S. Heimbach T, et al. Among authors: poggesi i. Clin Pharmacol Ther. 2021 Aug;110(2):297-310. doi: 10.1002/cpt.2125. Epub 2020 Dec 30. Clin Pharmacol Ther. 2021. PMID: 33270249 Free PMC article.

8

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.

Marostica E, Sukbuntherng J, Loury D, de Jong J, de Trixhe XW, Vermeulen A, De Nicolao G, O'Brien S, Byrd JC, Advani R, McGreivy J, Poggesi I. Marostica E, et al. Among authors: poggesi i. Cancer Chemother Pharmacol. 2015 Jan;75(1):111-21. doi: 10.1007/s00280-014-2617-3. Epub 2014 Nov 8. Cancer Chemother Pharmacol. 2015. PMID: 25381051 Clinical Trial.

9

Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency.

Coulomb F, Ducret F, Laneury JP, Fiorentini F, Poggesi I, Jannuzzo MG, Fleishaker JC, Houin G, Duchêne P. Coulomb F, et al. Among authors: poggesi i. J Clin Pharmacol. 2000 May;40(5):482-7. doi: 10.1177/00912700022009251. J Clin Pharmacol. 2000. PMID: 10806601 Clinical Trial.

10

Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity.

Tosca EM, Bartolucci R, Magni P, Poggesi I. Tosca EM, et al. Among authors: poggesi i. Expert Opin Drug Discov. 2021 Nov;16(11):1365-1390. doi: 10.1080/17460441.2021.1931114. Epub 2021 Jun 28. Expert Opin Drug Discov. 2021. PMID: 34181496 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

99 results

Search Page